The Next-Level LC-MS Technology Forum

Ever since the invention of electrospray ionization, LC-MS has risen through the ranks to become one of the most important tools in the analytical armamentarium. The application list grows longer every year, and advances in software, analytical power, and ease of use support the momentum of LC-MS, taking it to the next level.

Here, our panel of five experts will share innovation updates and words of wisdom – from method development to sample prep to specific applications – helping you score enough points to level-up your LC-MS analyses.

Agenda

James Hogbin and Stuart Berry, Application Scientists, ACD/Labs

Method complexity is certainly a factor in the time spent on development – but how you plan your experiments and choose your samples also affects development efficiency.

In our presentation, we’ll help you learn where software is most effective in method development and explore how to maximize your use of software to get the biggest time savings. You’ll also see ACD/Labs’ method development software in action.

Jennifer Fournier, Director of Product Marketing, Chemistry Technology Center, Waters Corporation

LC-MS sample preparation can be time intensive with many of the methods somewhat challenging to transfer between scientists. I’ll share a solution to help minimize variability, improve traceability, and simplify method transfers to bring improved efficiency to the lab – all while allowing scientists to increase productivity through the automation of routine and complex sample preparation.

Jonathan Spencer, LC-MS Applications Scientist, Agilent Technologies

I’ll explore the determination of several classes of emerging contaminants in food: chlorate and perchlorate, per/polyfluoroalkyl substances (PFAS), and pyrrolizidine alkaloids. And then discuss key analytical challenges presented by these compounds – and how we can address them, with the power of LC-MS.

Heidi Vitrac, Applications Scientist, Tosoh Bioscience LLC

Glycosylation determines pharmacological properties of biotherapeutics, including monoclonal antibodies (mAbs). Therefore, characterizing the heterogeneity of N-glycans in mAbs is part of their manufacturing and quality control. However, the different possible glycan structures can lead to numerous glycoisoforms for a given protein challenging their identification. A novel stationary phase uses a recombinant FcγRIIIa protein to profile affinity between mAb and Fc receptor which is regulated by mAb glycosylation. Two workflows used the stationary phase to characterize the effects of glycosylation on the functionally important affinity of mAb and Fc receptor: inline native ESI-MS and offline released N-glycans analysis by HILIC-MS/MS.

PLUS Live Q&A Session

Finally, our five experts will be on hand to help you take your LC-MS analyses to the next level!